



A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome [ClinicalTrials.gov Identifier: NCT03848832].

How long is the study? 2-4 weeks of baseline and 24 weeks of treatment followed by a 6-month open-label extension.

Participants will be randomly assigned to either placebo or active treatment groups (added to their existing medications). A placebo is a medicine that looks, smells, and tastes the same as GWP42003-P, but does not have any active ingredient (cannabidiol) in it.

All patients who complete the trial will be invited to participate in the open-label extension study, where all participants receive active treatment. Travel assistance may be provided on a case-by-case basis, if required.

Who is eligible? Participants must have a Rett syndrome diagnosis (typical or atypical) confirmed by clinical exam with the RettSearch Consortium revised diagnostic criteria. All medications or interventions for Rett syndrome related symptoms must be stable for 4 weeks prior to the trial. Some additional eligibility criteria are provided in the table below.

Criteria
Does your child have a definite diagnosis of Rett syndrome?
Does your child weigh at least 22 lbs?
Is your child at least two years old and not older than 18 years old?
Is your child able to swallow a medicine provided as a liquid solution, or is it possible to administer a liquid solution medicine via a gastrostomy (G) or nasogastric (NG) feeding tube? <i>(note your Doctor will have to check if the G-or NG-tube is adequate for dosing)</i>
Does your child regularly take 2 or less anti-epileptic medications?
Has your child abstained from the use of cannabis or cannabinoid-based therapies for the last 3 months?
Are you willing for your child to abstain from the use of any cannabis or cannabinoid-based therapies for the length of the study, if selected for the study?

If your response to all questions in the above table is yes, your child may be eligible to participate in this clinical trial.

Your child may not be eligible now but become eligible on a later date (for instance if their weight increases), so you may want to re-check their eligibility in a few months.

Please review the full summary of criteria at this [link](#). If you believe you are eligible to participate, contact GW Research by email medinfo@gbio.com